SERENITY

Antithrombotic therapy (ATT) has negligible positive effects on the well-being of terminally ill cancer patients. However, ATT is often continued until the patient dies, causing bleeding and increasing the burden of disease as well as healthcare costs. The EU-funded SERENITY project aims to develop a web-based, information-driven Shared Decision Support Tool (SDST) to facilitate strategy around the use of ATT in cancer patients at the end of life. The comprehensive approach adopted by the project will combine reviews, flash mob research, European epidemiological studies and qualitative interviews. The results will be used in a Delphi process to reach consensus on the optimal design of the OAPDP, which is intended to be patient-specific and adapted to socio-economic and disease-related factors.